Myasthenia Gravis

July 23rd 2025

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice and looks to the future of treatment for the autoimmune neuromuscular disorder.

July 15th 2025

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of Daily Living response, and Minimal Symptom Expression.

July 3rd 2025

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations.

June 24th 2025

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.